Insulin Biosimilars - Global Market Outlook (2017-2023)

  • ID: 4449948
  • Report
  • Region: Global
  • 167 pages
  • Stratistics Market Research Consulting Pvt Ltd
1 of 4

FEATURED COMPANIES

  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Merck & Co.
  • Mylan N.V.
  • NOVO Nordisk A/S
  • MORE
Growing pervasiveness of type 1 diabetes and ongoing approvals by the government authorities are nurturing the market growth. Some of the factors such as growing population exposures, technological developments and favorable medical repayment scenario in developed countries are poised to favour the market growth. However, patent protection rights of insulin and strong vengeance from the key manufacturers are some of the restraints limiting the market.

Expansion of clinically verified insulin biosimilar will cover the road for new entrants. The approaching patent expiration of insulin drugs will unlock new opportunities for the development of biosimilars and manufacturing companies. As cost is high due to strict observance requirements, prices of biosimilar drugs are anticipated to decrease as compared to branded drugs.

North America led the insulin biosimilars market due to rising demand for insulin in the region. Europe is anticipated to account for second largest share and Asia Pacific is expected to grow at a fastest rate during the forecast period. APAC players are competing on the basis of price and have pool of patients affected by diabetes, thus fueling the market growth.

Some of the key players in this market are Wockhardt Limited, Ypsomed AG, Pfizer Inc., Mylan N.V., Boehringer Ingelheim GmbH, NOVO Nordisk A/S, Sanofi S.A., Merck & Co., Biocon Limited and Eli Lilly & Co.

Biosimilars Types Covered
  • Rapid-Acting Biosimilars
  • Long-Acting Biosimilars
  • Premixed Biosimilars
Disease Indications Covered
  • Type I Diabetes
  • Type II Diabetes
Regions Covered:
  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • Italy
  • France
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
  • South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa
What our report offers:
  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Merck & Co.
  • Mylan N.V.
  • NOVO Nordisk A/S
  • MORE
1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Insulin Biosimilars Market, By Biosimilars Type
5.1 Introduction
5.2 Rapid-Acting Biosimilars
5.3 Long-Acting Biosimilars
5.4 Premixed Biosimilars

6 Global Insulin Biosimilars Market, By Disease Indication
6.1 Introduction
6.2 Type I Diabetes
6.3 Type II Diabetes

7 Global Insulin Biosimilars Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa

8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiling
9.1 Wockhardt Limited
9.2 Ypsomed AG
9.3 Pfizer Inc.
9.4 Mylan N.V.
9.5 Boehringer Ingelheim GmbH
9.6 NOVO Nordisk A/S
9.7 Sanofi S.A.
9.8 Merck & Co.
9.9 Biocon Limited
9.10 Eli Lilly & Co.

List of Tables:
Table 1 Global Insulin Biosimilars Market Outlook, By Region (2014-2023) ($MN)
Table 2 Global Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
Table 3 Global Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
Table 4 Global Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
Table 5 Global Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
Table 6 Global Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
Table 7 Global Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
Table 8 Global Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
Table 9 North America Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
Table 10 North America Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
Table 11 North America Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
Table 12 North America Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
Table 13 North America Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
Table 14 North America Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
Table 15 North America Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
Table 16 North America Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
Table 17 Europe Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
Table 18 Europe Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
Table 19 Europe Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
Table 20 Europe Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
Table 21 Europe Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
Table 22 Europe Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
Table 23 Europe Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
Table 24 Europe Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
Table 25 Asia Pacific Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
Table 26 Asia Pacific Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
Table 27 Asia Pacific Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
Table 28 Asia Pacific Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
Table 29 Asia Pacific Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
Table 30 Asia Pacific Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
Table 31 Asia Pacific Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
Table 32 Asia Pacific Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
Table 33 South America Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
Table 34 South America Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
Table 35 South America Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
Table 36 South America Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
Table 37 South America Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
Table 38 South America Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
Table 39 South America Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
Table 40 South America Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
Table 41 Middle East & Africa Insulin Biosimilars Market Outlook, By Country (2014-2023) ($MN)
Table 42 Middle East & Africa Insulin Biosimilars Market Outlook, By Biosimilars Type (2014-2023) ($MN)
Table 43 Middle East & Africa Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2014-2023) ($MN)
Table 44 Middle East & Africa Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2014-2023) ($MN)
Table 45 Middle East & Africa Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2014-2023) ($MN)
Table 46 Middle East & Africa Insulin Biosimilars Market Outlook, By Disease Indication (2014-2023) ($MN)
Table 47 Middle East & Africa Insulin Biosimilars Market Outlook, By Type I Diabetes (2014-2023) ($MN)
Table 48 Middle East & Africa Insulin Biosimilars Market Outlook, By Type II Diabetes (2014-2023) ($MN)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Wockhardt Limited
  • Ypsomed AG
  • Pfizer Inc.
  • Mylan N.V.
  • Boehringer Ingelheim GmbH
  • NOVO Nordisk A/S
  • Sanofi S.A.
  • Merck & Co.
  • Biocon Limited
  • Eli Lilly & Co.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll